PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Identification and validation of the Hsa_circ_0001726/miR-140-3p/KRAS axis in hepatocellular carcinoma based on microarray analyses and experiments

Identification and validation of the Hsa_circ_0001726/miR-140-3p/KRAS axis in hepatocellular carcinoma based on microarray analyses and experiments
2024-10-27
(Press-News.org) Background and Aims Hepatocellular carcinoma (HCC) is one of the most fatal malignancies. Epigenetic mechanisms have revealed that noncoding RNAs, such as microRNAs (miRNAs) and circular RNAs (circRNAs), are involved in HCC progression. This study aimed to construct a circRNA-miRNA-mRNA network in HCC and validate one axis within the network.

Methods HCC-related transcriptome data were obtained from the Gene Expression Omnibus, and HCC-related genes were sourced from GeneCards to identify differentially expressed circRNAs and miRNAs. The targeting relationships between circRNA-miRNA and miRNA-mRNA interactions were predicted. The involvement of the hsa_circ_0001726/miR-140-3p/KRAS axis in HCC was evaluated through cellular experiments and survival analyses.

Results We identified six differentially expressed circRNAs in HCC, which were linked to 13 miRNAs and 88 mRNAs. A network containing 34 circRNA-miRNA pairs and 194 miRNA-mRNA pairs was constructed. Cell proliferation and migration assays confirmed the role of hsa_circ_0001726 in promoting HCC progression, possibly through the miR-140-3p/KRAS axis. Survival analysis verified that hsa_circ_0001726 was a prognostic factor for overall survival in patients with HCC. The hsa_circ_0001726/miR-140-3p/KRAS axis also mediates lenvatinib resistance in HCC cells.

Conclusions The HCC circRNA/miRNA/mRNA network provides new insights into the post-transcriptional regulatory mechanism of HCC. The hsa_circ_0001726/miR-140-3p/KRAS axis is involved in HCC progression and lenvatinib resistance.

 

Full text

https://www.xiahepublishing.com/2310-8819/JCTH-2024-00270

 

The study was recently published in the Journal of Clinical and Translational Hepatology.

The Journal of Clinical and Translational Hepatology (JCTH) is owned by the Second Affiliated Hospital of Chongqing Medical University and published by XIA & HE Publishing Inc. JCTH publishes high quality, peer reviewed studies in the translational and clinical human health sciences of liver diseases. JCTH has established high standards for publication of original research, which are characterized by a study’s novelty, quality, and ethical conduct in the scientific process as well as in the communication of the research findings. Each issue includes articles by leading authorities on topics in hepatology that are germane to the most current challenges in the field. Special features include reports on the latest advances in drug development and technology that are relevant to liver diseases. Regular features of JCTH also include editorials, correspondences and invited commentaries on rapidly progressing areas in hepatology. All articles published by JCTH, both solicited and unsolicited, must pass our rigorous peer review process.

Follow us on X: @xiahepublishing

Follow us on LinkedIn: Xia & He Publishing Inc.

END


[Attachments] See images for this press release:
Identification and validation of the Hsa_circ_0001726/miR-140-3p/KRAS axis in hepatocellular carcinoma based on microarray analyses and experiments

ELSE PRESS RELEASES FROM THIS DATE:

New study warns that melting Arctic sea-ice could affect global ocean circulation

New study warns that melting Arctic sea-ice could affect global ocean circulation
2024-10-27
“Our finding that enhanced melting of Arctic sea-ice likely resulted in significant cooling in northern Europe in the earth’s past is alarming,” says Mohamed Ezat from the iC3 Polar Research Hub, lead author of the new study. “This reminds us that the planet’s climate is a delicate balance, easily disrupted by changes in temperature and ice cover.”  Ice-free summer conditions are expected to occur in the Arctic Ocean from the year 2050 onwards.  Earlier this ...

Researchers test imlifidase enzyme versus plasma exchange in removing donor-specific antibodies in kidney transplant rejection trial

2024-10-27
San Diego, CA (October 26, 2024) — For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney ...

Preclinical studies test novel gene therapy for treating IgA nephropathy

2024-10-26
San Diego, CA (October 26, 2024) — IgA nephropathy is an autoimmune kidney disease, and complement, a component of the innate immune system, plays a role in the condition’s pathogenesis. Investigators have developed and tested a novel gene therapy that enters kidney cells and enables them to block complement activation. The research will be presented at ASN Kidney Week 2024 October 23– 27. The gene therapy, called PS-002, uses a modified virus to treat kidney cells called podocytes. Administration of PS-002 in a mouse model of IgA nephropathy reduced signs of kidney dysfunction, lowered complement ...

Trial assesses antibody therapy for chronic active antibody-mediated kidney transplant rejection

2024-10-26
San Diego, CA (October 26, 2024) — Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be ...

High-impact clinical trials generate promising results for improving kidney health: Part 2

2024-10-26
The results of numerous high-impact phase 3 clinical trials that could affect kidney-related medical care will be presented in-person at ASN Kidney Week 2024 October 23–27. Hyponatremia, or a chronically low blood salt level, is the most common electrolyte disorder in hospitalized patients, and is associated with higher risks of death and re-hospitalization. In a recent trial, 2,173 hospitalized patients with hyponatremia from 9 centers across Europe were assigned to undergo either targeted correction of blood salt levels according to guidelines or to receive routine care for hyponatremia. The primary outcome was the combined ...

Expression of carbonic anhydrase IX as a novel diagnostic marker for differentiating pleural mesothelioma from non-small cell lung carcinoma

Expression of carbonic anhydrase IX as a novel diagnostic marker for differentiating pleural mesothelioma from non-small cell lung carcinoma
2024-10-26
Background and objectives Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Carbonic anhydrase IX (CAIX) is a transmembrane protein that is overexpressed in a variety of solid tumors. This study aimed to investigate the clinical utility of CAIX expression in the differential diagnosis of pleural mesothelioma from non-small cell lung carcinoma (NSCLC). Methods Unstained tissue microarray slides composed of 56 cases of pleural mesothelioma and 82 cases of NSCLC were subjected to immunohistochemical staining using a mouse anti-human antibody against CAIX. Results Of the 38 epithelioid mesothelioma ...

In silico assessment of photosystem I P700 chlorophyll a apoprotein A2 (PsaB) from Chlorella vulgaris (green microalga) as a source of bioactive peptides

In silico assessment of photosystem I P700 chlorophyll a apoprotein A2 (PsaB) from Chlorella vulgaris (green microalga) as a source of bioactive peptides
2024-10-26
Background and objectives Chlorella vulgaris is a green, photosynthetic microalga in the phylum Chlorophyta. The goal of our study was to perform a bioinformatics analysis of Photosystem I P700 chlorophyll a apoprotein A2, one of its photosynthesis-related proteins, and to hunt for potent bioactive peptides. Methods To generate peptides and estimate the safety and efficacy of each bioactive peptide, we employed the tools BIOPEP-UWM™, PeptideRanker, DBAASP, and ToxinPred. PepDraw was used to understand the physicochemical properties ...

Association between TLR10 rs10004195 gene polymorphism and risk of Helicobacter pylori infection

2024-10-26
Background and objectives Helicobacter pylori (H. pylori) infection can cause multiple secondary digestive disorders. Some studies have found that polymorphisms in Toll-like receptor (TLR) genes, including TLR10 rs10004195, may be associated with increased susceptibility to H. pylori infection. Despite conflicting reports, we conducted a meta-analysis to clarify the relationship between these factors. Methods We conducted an exhaustive review, encompassing all relevant literature up to February 2024, using databases ...

The usefulness of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry in the diagnosis of onychomycosis in patients with nail psoriasis

2024-10-26
Background and objectives Nail psoriasis is common in patients with plaque psoriasis and is associated with morbidity, including onychomycosis, which can complicate psoriasis treatments and be difficult to differentiate. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry is a fast and simple technique for identifying microorganisms through protein analysis. This study aimed to determine the sensitivity and specificity of MALDI-TOF for diagnosing onychomycosis in patients with nail psoriasis, by using conventional mycological and histological methods as the reference standard. Methods A prospective study was conducted on 88 patients with ...

Liver characterization of a cohort of alpha-1 antitrypsin deficiency patients with and without lung disease

2024-10-26
Background and Aims Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder characterized by the misfolding and accumulation of the mutant variant of alpha-1 antitrypsin (AAT) within hepatocytes, which limits its access to the circulation and exposes the lungs to protease-mediated tissue damage. This results in progressive liver disease secondary to AAT polymerization and accumulation, and chronic obstructive pulmonary disease (COPD) due to deficient levels of AAT within the lungs. Our goal was to characterize the unique effects of COPD secondary to AATD on liver disease and gene expression. Methods A ...

LAST 30 PRESS RELEASES:

Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation

Fractional flow reserve–guided complete vs culprit-only revascularization in non–ST-elevation myocardial infarction and multivessel disease

Participation of women in cardiovascular trials from 2017 to 2023

Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction

Changes in biology of internal fat may be the leading cause of heart failure

Transcatheter or surgical treatment of patients with aortic stenosis at low to intermediate risk

Promising new drug for people with stubborn high blood pressure

One shot of RSV vaccine effective against hospitalization in older adults for two seasons

Bivalent RSV prefusion F protein–based vaccine for preventing cardiovascular hospitalizations in older adults

Clonal hematopoiesis and risk of new-onset myocarditis and pericarditis

Risk of myocarditis or pericarditis with high-dose vs standard-dose influenza vaccine

High-dose vs standard-dose influenza vaccine and cardiovascular outcomes in older adults

Prevalence, determinants, and time trends of cardiovascular health in the WHO African region

New study finds that, after a heart attack, women have worse prognosis when treated with beta-blockers

CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients

Systolic blood pressure and microaxial flow pump–associated survival in infarct-related cardiogenic shock

Beta blockers, the standard treatment after a heart attack, may offer no benefit for heart attack patients and women can have worse outcomes

High Mountain Asia’s shrinking glaciers linked to monsoon changes

All DRII-ed up: How do plants recover after drought?

Research on stigma says to just ‘shake it off’

Scientists track lightning “pollution” in real time using NASA satellite

Millions of women rely on contraceptives, but new Rice study shows they may do more than just prevent pregnancy

Hot days make for icy weather, Philippine study finds

Roxana Mehran, MD, receives the most prestigious award given by the European Society of Cardiology

World's first clinical trial showing lubiprostone aids kidney function

Capturing language change through the genes

Public trust in elections increases with clear facts

Thawing permafrost raised carbon dioxide levels after the last ice age

New DNA test reveals plants’ hidden climate role

Retinitis pigmentosa mouse models reflect pathobiology of human RP59

[Press-News.org] Identification and validation of the Hsa_circ_0001726/miR-140-3p/KRAS axis in hepatocellular carcinoma based on microarray analyses and experiments